polyethylene glycol
Approved
Jul 13, 1984
PEG or peg may refer to: — Wikipedia
Clinical trial activity
420 trials · 365 clinical orgs · 30 marketing orgs
Earliest trial started Apr 1, 1998 (NCT00288496)
Timeline
1980s
- Jul 13, 1984
Earliest FDA Approval
- Jul 13, 1984
Braintree Laboratories — NDA Secondary Org
- Oct 26, 1984
Block Drug — First NDA Organization
- Oct 26, 1984
Block Drug — NDA Organization
- Oct 26, 1984
Mylan — NDA Secondary Org
- Apr 30, 1986
Hospira — Marketing Organization
- Apr 30, 1986
Hospira — NDA Secondary Org
- Apr 20, 1988
Dynapharm — Marketing Organization
- Dec 23, 1988
Goldline — Marketing Organization
1990s
- Jan 28, 1992
Vintage — Marketing Organization
- Jan 1, 1999
Braintree Laboratories — Earliest Phase 3 Sponsor(trial)
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
- Jul 2, 2004
Lannett Company, Inc. — Marketing Organization
- May 4, 2006
Teva — Marketing Organization
- May 24, 2006
Paddock Laboratories — Marketing Organization
- May 26, 2006
Esteve Labs — Marketing Organization
- Aug 2, 2006
Salix — Marketing Organization
- Aug 2, 2006
Salix — NDA Secondary Org
- Sep 27, 2006
Nexgen Pharma, Inc — Marketing Organization
- Oct 6, 2006
Bayer — NDA Secondary Org
- May 27, 2009
Novel Anti-Infective Technologies, LLC — Marketing Organization
- Oct 6, 2009
Mylan — Marketing Organization
- Oct 6, 2009
Perrigo — Marketing Organization
- Oct 7, 2009
LGM Pharma — Marketing Organization
2010s
- Dec 28, 2012
Apnar Pharma — Marketing Organization
- Dec 28, 2012
Novelgenix Therapeutics — Marketing Organization
- Dec 28, 2012
Elysium Health — Marketing Organization
- Jan 18, 2013
Braintree Laboratories — Marketing Organization
- Jan 31, 2013
Par Pharmaceuticals — Marketing Organization
- Apr 13, 2015
Strides Pharma Science — Marketing Organization
- Dec 15, 2015
Ani Pharmaceuticals — Marketing Organization
- Oct 28, 2016
Nuvo Research Inc. — Marketing Organization
- Mar 8, 2017
Nostrum Laboratories — Marketing Organization
- Apr 9, 2018
Aurobindo Pharma — Marketing Organization
- May 4, 2018
Bausch Health Companies — NDA Secondary Org
2020s
- Apr 14, 2021
Annora Pharma — Marketing Organization
Indications
Approved for
Studied for
- Acute-On-Chronic Liver Failure · Phase 4
- Adenoma · Phase 4
- Allergy and Immunology · Phase 1
- Anastomotic Leak · Phase 3
- Autism Spectrum Disorder · Phase 2
- Blepharitis · Phase 3
- Capsule Endoscopy · Phase 4
- Carcinoma, Pancreatic Ductal · Phase 1
- Cataract · Phase 4
- Cathartics · Phase 4
- Celiac Disease · Phase 4
- Clostridioides difficile · Phase 2/Phase 3
- Clostridium Infections · Phase 4
- Colitis, Ulcerative · Phase 4
- Colon · Phase 4
- Colonic Diseases · Phase 4
- Colonic Neoplasms · Phase 4
- Colonic Polyps · Phase 4
- Colonoscopy · Phase 4
- Colorectal Neoplasms · Phase 4
- Colorectal Surgery · Phase 4
- Constipation · Phase 4
- Critical Illness · Phase 3
- Crohn Disease · Phase 4
- Cystic Fibrosis · Phase 4
- Defecation · Phase 4
- Dermatology · Phase 2
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 2 · Phase 3
- Diabetic Retinopathy · Phase 2
- Diagnosis · Phase 4
- Dialysis · Phase 4
- Diarrhea · Phase 2
- Digestive System Diseases · Phase 3
- Diurnal Enuresis · Phase 4
- Diverticulitis · Early Phase 1
- Diverticulum · Phase 4
- Drug Resistance, Bacterial · Phase 1/Phase 2
- Drugs, Investigational · Phase 4
- Dry Eye Syndromes · Phase 4
- Dysbiosis · Phase 4
- Dyskinesias · Phase 3
- Endoscopy · Phase 4
- Exanthema · Phase 2
- Facial Paralysis · Phase 2
- Fear · Phase 2/Phase 3
- Fecal Impaction · Phase 4
- Feces · Phase 4
- Fissure in Ano · Phase 4
- Gastric Emptying · Phase 1
- Gastrointestinal Diseases · Phase 4
- Gastrointestinal Hemorrhage · Phase 4
- Gender Dysphoria · Phase 2/Phase 3
- General Surgery · Phase 4
- Glaucoma, Open-Angle · Phase 4
- Glycemic Control · Phase 2
- Hamartoma · Phase 4
- Hand Injuries · Phase 1
- Healthy Volunteers · Phase 4
- Hemorrhage · Phase 3
- Hepacivirus · Phase 2
- Hepatic Encephalopathy · Phase 4
- Hepatitis C · Phase 3
- Hepatitis C, Chronic · Phase 3
- HIV · Phase 1/Phase 2
- Hospitalization · Phase 4
- Hyperkalemia · Phase 4
- Infections · Phase 2/Phase 3
- Inflammatory Bowel Diseases · Phase 4
- Intestinal Diseases · Phase 4
- Intestinal Neoplasms · Phase 4
- Intestine, Large · Phase 4
- Kidney Neoplasms · Phase 4
- Klebsiella pneumoniae · Phase 1/Phase 2
- Lactulose · Phase 4
- Macular Edema · Phase 2
- Magnesium Sulfate · Phase 2
- Melanoma · Phase 2
- Motor Activity · Phase 3
- Myopia · Phase 4
- Neoplasm Metastasis · Early Phase 1
- Neoplasms · Phase 4
- Nerve Fibers · Phase 3
- Nocturnal Enuresis · Phase 4
- Ophthalmology · Phase 4
- Parkinson Disease · Phase 3
- Peripheral Nerve Injuries · Phase 3
- Polyethylene Glycols · Phase 4
- Postoperative Complications · Phase 4
- Pregnancy Complications · Phase 2/Phase 3
- Prolapse · Phase 4
- Prostatic Neoplasms · Phase 4
- Radiodermatitis · Phase 2
- Renal Insufficiency, Chronic · Phase 4
- Retinal Diseases · Phase 2/Phase 3
- Sarcoma · Early Phase 1
- Staphylococcal Infections · Phase 4
- Surgical Wound Infection · Early Phase 1
- Tears · Phase 1
- Venous Cutdown · Phase 3
- Vision Disorders · Phase 4
- Vitreoretinopathy, Proliferative · Phase 2/Phase 3
- Xerophthalmia · Phase 3
Mechanism of action
- Unspecified targetOTHER
Osmotic laxative
- UnclearUnclear
Unclear unclear
Combination products
golytely
with potassium chloride, sodium sulfate, sodium bicarbonate, sodium chloride
Also known as clenz-lyte, co-lav, colovage, colyte, colyte-flavore, colyte with flavor packs, glycoprep, go-evac, ocl, peg 3350 and electrolytes, polyethylene glycol 3350 and electrolytes
halflytely
with bisacodyl, potassium chloride, sodium bicarbonate, sodium chloride
Also known as peg-3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodyl
moviprep
with vitamin c, potassium chloride, sodium sulfate, sodium chloride
Also known as peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic aci, plenvu
nulytely-flavore
with potassium chloride, sodium bicarbonate, sodium chloride
Also known as lax-lyte with flavor packs, nulytely, peg-3350, potassium chloride, sodium bicarbonate, sodium chloride, trilyte
suclear
with potassium chloride, magnesium sulfate, potassium sulfate, sodium sulfate, sodium bicarbonate, sodium chloride
suflave
with potassium chloride, magnesium sulfate, sodium sulfate, sodium chloride
Approval history
- approvedJul 13, 1984
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- Yes
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPeg ↗
- NCATSG2M7P15E5P ↗
- WikipediaPolyethylene glycol ↗
- WikipediaPEG ↗
- WikipediaMacrogol ↗
- WikipediaAlcon ↗
- NCATSUH6KR4953D ↗
- NCATSUEP843BRCQ ↗
- NCATSU076Q6Q621 ↗
- NCATSTVH7653921 ↗
- NCATSSA1B764746 ↗
- NCATSR95B8J264J ↗
- NCATSQ662QK8M3B ↗
- NCATSOJ4Z5Z32L4 ↗
- NCATSNL4J9F21N9 ↗
- NCATSFVS1AZD90Y ↗
- NCATSB697894SGQ ↗
- NCATS5WKN5KL2O8 ↗
- NCATS5655G9Y8AQ ↗
- NCATS30IQX730WE ↗
- ChEMBLCHEMBL1201479 ↗
- NCATS1212Z7S33A ↗
- ChEMBLCHEMBL1201478 ↗
Also known as
- ajg555
- asp3350
- bli4700
- colyte
- colyte
- colyte
- dcl-101
- e1521
- glycolax
- golytely
- isocolan
- lutrol e
- macrogol 3350
- macrogol 4000
- macrogol 4000
- macrogol 6000
- macrogolol
- miralax
- miralax
- miralax
- miralax
- nulytely
- peg
- peg
- peg
- peg3350
- peg 3350
- peg-3350
- peg-3350
- peg 400
- peg-400
- peg-400
- peg-400
- peo-400
- pluracol e
- pluracol e
- poe
- poe
- polyethelene glycol
- polyethylene glycol
- polyethylene glycol
- polyethylene glycol
- polyethylene glycol
- polyethylene glycol
- polyethylene glycol
- polyethylene glycol
- polyethylene glycol 300
- polyethylene glycol 3350
- polyethylene glycol 3350
- polyethylene glycol 3350
- polyethylene glycol 3350
- polyethylene glycol 3350
- polyethylene glycol 3350
- polyethylene glycol 3350
- polyethylene glycol 3350
- polyethylene glycol 400
- polyethylene glycol 400
- polyethylene glycol 400
- polyethylene glycol 400
- polyethylene glycol 400
- polyethylene glycol 4000
- polyethylene glycol 4000
- polyethylene glycol 6000
- polyethylene glycol 6000
- polyethylene oxide
- polyethylene oxide
- polyglycol e 300, e 400, e 1450, e 8000
- polyoxyethylene
- polyoxyethylene
- sf-els
- suclear
- systane
- systane
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07201311 | Phase 2 | Nov 30, 2025 | Assistance Publique - Hôpitaux de Paris |
| NCT07084350 | N/A | Aug 25, 2025 | People's Liberation Army of China |
| NCT07048886 | Phase 4 | Jul 15, 2025 | Center for Sight |
| NCT06966349 | Phase 4 | Jun 10, 2025 | University of Waterloo |
| NCT06836024 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2025 | Hamilton Health Sciences Corporation |
| NCT06919120 | Phase 4 | Jun 1, 2025 | Zhejiang University |
| NCT06975891 | Phase 4 | May 15, 2025 | Scripps, Sengi |
| NCT06825260 | Phase 4 | Mar 31, 2025 | St. Joseph's Health, New York |
| NCT06616025 | Phase 3 | Jan 31, 2025 | Neuraptive Therapeutics Inc. |
| NCT06722209 | N/A | Dec 10, 2024 | Eastern Mediterranean University |
| NCT06728839 | N/A | Dec 9, 2024 | Central Hospital, Zibo, Changhai Hospital, Henan Medical University, Jiangmen Central Hospital, Jiao Tong University, Nanchang University, People's Liberation Army of China, Shandong Province Qianfoshan Hospital, Wenzhou Medical University, Yan'an University Affiliated Hospital, Yueqing People's Hospital, Zhengzhou University |
| NCT06831539 | Phase 1 | Dec 5, 2024 | University of Montreal |
| NCT06690632 | N/A | Dec 1, 2024 | University of Toulouse |
| NCT06633471 | Early Phase 1 (Phase 1) | Nov 4, 2024 | PS Therapy Inc. |
| NCT06379685 | Phase 1 | Sep 30, 2024 | Laboratorios Sophia S.A de C.V. |
| NCT06748638 | Phase 4 | Sep 1, 2024 | Jinlin University, Nanjing Medical University |
| NCT06503978 | Phase 2 | Aug 20, 2024 | Gut-Brain-Axis Therapeutics Inc. |
| NCT06298461 | Phase 4 | May 31, 2024 | University of Manitoba |
| NCT06357897 | N/A | May 31, 2024 | Chulalongkorn University |
| NCT06393400 | Phase 1 | May 27, 2024 | University of Western Ontario |
Organizations
Research & Development (365)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alcon | For profit | 32 | 28 | 4 | 2005 |
| Braintree Laboratories | For profit | 26 | 26 | 3 | 1999 |
| Norgine | For profit | 19 | 16 | 5 | 2000 |
| Shandong University | Academic/Hospital | 12 | 9 | 4 | 2015 |
| People's Liberation Army of China | Government | 11 | 6 | 2 | 2014 |
| Gilead Sciences | For profit | 9 | 9 | 2 | 2010 |
| Jiao Tong University | Academic/Hospital | 8 | 2 | 4 | 2010 |
| Changhai Hospital | Academic/Hospital | 7 | 7 | 3 | 2014 |
| Bayer | For profit | 6 | 5 | 3 | 2007 |
| Laboratorios Sophia S.A de C.V. | For profit | 6 | 6 | 4 | 2011 |
| Tel Aviv University | Academic/Hospital | 6 | 5 | 3 | 2008 |
| AbbVie | For profit | 5 | 5 | 1 | 2008 |
| Bp Consulting, Inc | For profit | 5 | 5 | 1 | 2008 |
| Ferring | For profit | 5 | 5 | 2 | 2010 |
| Mayo Clinic | Academic/Hospital | 5 | 4 | 3 | 2007 |
| Department of Veteran Affairs | Government | 4 | 4 | 2 | 2005 |
| Inje University | Academic/Hospital | 4 | 4 | 2 | 2010 |
| Innovative Medical Research of South Florida, Inc | For profit | 4 | 4 | 1 | 2006 |
| IQVIA | For profit | 4 | 0 | 1 | 2008 |
| Korea University | Academic/Hospital | 4 | 4 | 1 | 2012 |
Marketing (43)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ani Pharmaceuticals | For profit | MKTG | Dec 15, 2015 |
| Ani Pharmaceuticals | For profit | SYN | Dec 15, 2015 |
| Annora Pharma | For profit | MKTG | Apr 14, 2021 |
| Apnar Pharma | For profit | MKTG | Dec 28, 2012 |
| Aurobindo Pharma | For profit | MKTG | Apr 9, 2018 |
| Aurobindo Pharma | For profit | SYN | Feb 5, 2004 |
| Bausch Health Companies | For profit | NDA2 | May 4, 2018 |
| Bayer | For profit | NDA2 | Oct 6, 2006 |
| Block Drug | For profit | NDA | Oct 26, 1984 |
| Braintree Laboratories | For profit | NDA2 | Jul 13, 1984 |
| Braintree Laboratories | For profit | MKTG | Jan 18, 2013 |
| Dynapharm | For profit | MKTG | Apr 20, 1988 |
| E Z EM | For profit | MKTG | — |
| Elysium Health | For profit | MKTG | Dec 28, 2012 |
| Esteve Labs | For profit | MKTG | May 26, 2006 |
| Esteve Labs | For profit | SYN | Mar 8, 2017 |
| Goldline | For profit | MKTG | Dec 23, 1988 |
| Hospira | For profit | MKTG | Apr 30, 1986 |
| Hospira | For profit | NDA2 | Apr 30, 1986 |
| LGM Pharma | For profit | MKTG | Oct 7, 2009 |
| Lannett Company, Inc. | For profit | MKTG | Jul 2, 2004 |
| Mylan | For profit | MKTG | Oct 6, 2009 |
| Mylan | For profit | SYN | Feb 5, 2004 |
| Mylan | For profit | SYN | Oct 26, 1984 |
| Mylan | For profit | NDA2 | Oct 26, 1984 |
| Nexgen Pharma, Inc | For profit | SYN | Oct 7, 2009 |
| Nexgen Pharma, Inc | For profit | MKTG | Sep 27, 2006 |
| Nostrum Laboratories | For profit | MKTG | Mar 8, 2017 |
| Novel Anti-Infective Technologies, LLC | For profit | MKTG | May 27, 2009 |
| Novelgenix Therapeutics | For profit | MKTG | Dec 28, 2012 |
| Nuvo Research Inc. | For profit | MKTG | Oct 28, 2016 |
| Paddock Laboratories | For profit | MKTG | May 24, 2006 |
| Par Pharmaceuticals | For profit | MKTG | Jan 31, 2013 |
| Perrigo | For profit | MKTG | Oct 6, 2009 |
| Perrigo | For profit | SYN | Feb 25, 2010 |
| Salix | For profit | MKTG | Aug 2, 2006 |
| Salix | For profit | SYN | May 4, 2018 |
| Salix | For profit | SYN | May 4, 2018 |
| Salix | For profit | NDA2 | Aug 2, 2006 |
| Sandoz | For profit | MKTG | — |
| Strides Pharma Science | For profit | MKTG | Apr 13, 2015 |
| Teva | For profit | MKTG | May 4, 2006 |
| Vintage | For profit | MKTG | Jan 28, 1992 |